Richard S Finkel

39PUBLICATIONS
153CO-AUTHORS
Neurology and neuromuscular diseasesGene and molecular therapyNeural engineeringInfant and child healthMedical robotics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (39)

|Jun 17, 2026
Ten years of disease-modifying therapy in spinal muscular atrophy: lessons learned and future directions.

|Jun 10, 2026
Onasemnogene Abeparvovec in Patients With SMA: Interim Results of the RESTORE Registry in Japan.

|Apr 23, 2026
Author Correction: High-dose nusinersen for spinal muscular atrophy: a phase 3 randomized trial.

|Feb 03, 2026
High-dose nusinersen for spinal muscular atrophy: a phase 3 randomized trial.

Richard S Finkel, Thomas O Crawford, Eugenio Mercuri

|Dec 08, 2025
Intrathecal onasemnogene abeparvovec in treatment-naive patients with spinal muscular atrophy: a phase 3, randomized controlled trial.

Crystal M Proud, Dũng Chí Vũ, Jo M Wilmshurst

|Nov 25, 2025
Ad astra per aspera: treatment challenges and opportunities for children with spinal muscular atrophy and tracheostomy.

Yasemin Erbas, Richard S Finkel

Pageof 7

Frequent Collaborators

8 joint publications

Francesco Muntoni

7 joint publications

Davide Pareyson

5 joint publications

Jacqueline Montes

5 joint publications

Chiara Pisciotta